Sonnet BioTherapeutics Holdings, Inc. revenue breakdown overview

Sonnet BioTherapeutics Holdings, Inc. revenue for the last year amounted to 147.81 k USD, the most of which — 147.81 k USD — came from its highest performing source at the moment, Immuno-oncology Treatments, the year earlier bringing 349.94 k USD. The greatest contribution to the revenue figure was made by United States — last year it brought Sonnet BioTherapeutics Holdings, Inc. 147.81 k USD, and the year before that — 349.94 k USD.